Tectonic Therapeutic (TECX) Cash from Financing Activities (2017 - 2026)
Tectonic Therapeutic (TECX) reported Cash from Financing Activities of $847000.0 for Q1 2026, down 99.52% year-over-year from $178.1 million in Q1 2025, and up 700.71% quarter-over-quarter from -$141000.0 in Q4 2025.
Tectonic Therapeutic (TECX) Cash from Financing Activities (2017 - 2026) Analysis & Trends
Tectonic Therapeutic (TECX) has 10 years of Cash from Financing Activities data on file, last reported at $847000.0 in Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at $847000.0, down 99.52% year-over-year; the trailing twelve-month figure through Mar 2026 was -$3.9 million (down 101.12% YoY), and the FY2025 annual result was $173.4 million, up 0.96% from the prior year.
- Cash from Financing Activities grew to $847000.0 in Q1 2026 per TECX's latest filing, from -$141000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $179.7 million in Q2 2024 and troughed at -$6.3 million in Q3 2024.
- A 5-year average of $22.3 million and a median of $1000.0 in 2022 frame the typical range for Cash from Financing Activities.
- On a YoY basis, Cash from Financing Activities climbed as much as 57747.46% in 2023 and fell as far as 32500.0% in 2023.
- A 5-year view of Cash from Financing Activities shows it stood at $59000.0 in 2022, then surged by 57747.46% to $34.1 million in 2023, then slumped by 103.13% to -$1.1 million in 2024, then soared by 86.81% to -$141000.0 in 2025, then soared by 700.71% to $847000.0 in 2026.
- Business Quant data shows TECX's Cash from Financing Activities at $847000.0 in Q1 2026, -$141000.0 in Q4 2025, and -$457000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 53,000.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 85,464.43 |
| 10 | Tectonic Therapeutic | 528.16 Mn | 291.27 Mn | - | 847,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 847,000.00 |
| Mar 31, 2026 | 847,000.00 |
| Dec 31, 2025 | -141,000.00 |
| Dec 31, 2025 | -141,000.00 |
| Sep 30, 2025 | -457,000.00 |
| Sep 30, 2025 | -457,000.00 |
| Jun 30, 2025 | -4.17 Mn |
| Jun 30, 2025 | -4.17 Mn |
| Mar 31, 2025 | 178.12 Mn |
| Mar 31, 2025 | 178.12 Mn |
| Dec 31, 2024 | -1.07 Mn |
| Dec 31, 2024 | -1.07 Mn |
| Sep 30, 2024 | -6.29 Mn |
| Sep 30, 2024 | -6.29 Mn |
| Jun 30, 2024 | 179.74 Mn |
| Jun 30, 2024 | 179.74 Mn |
| Mar 31, 2024 | -668,000.00 |
| Mar 31, 2024 | -668,000.00 |
| Dec 31, 2023 | 34.13 Mn |
| Dec 31, 2023 | 34.13 Mn |